Genscript Flags Legend Biotech’s 2025 Results, Cautions Investors on Risk

Genscript Biotech ( (HK:1548) ) just unveiled an announcement.

Genscript Biotech has announced that its associate, Legend Biotech Corporation, has filed its fourth-quarter and full-year 2025 financial results and recent business highlights with the U.S. Securities and Exchange Commission via a Form 6-K. The company emphasized that these financial figures relate solely to Legend and not to Genscript itself, and urged shareholders and potential investors to remain mindful of investment risks and exercise caution when trading Genscript’s securities.

The disclosure underscores Genscript’s role as a significant stakeholder in a Nasdaq-listed biotech peer and provides investors with indirect insight into the performance of its associate. However, Genscript made clear that no inference should be drawn about its own financial condition from Legend’s results, reinforcing the need for investors to distinguish between the two entities when making investment decisions.

The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

More about Genscript Biotech

Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong, with business interests that include an equity stake in Nasdaq-listed Legend Biotech Corporation. Legend operates as an associate of Genscript, reflecting Genscript’s exposure to global biopharmaceutical markets through this U.S.-listed affiliate.

Average Trading Volume: 8,618,525

Technical Sentiment Signal: Sell

Current Market Cap: HK$25.41B

Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.